Rongchang Biotech announced that the company plans to repurchase shares through centralized bidding transactions, with an amount not less than 20 million yuan and no more than 40 million yuan. The repurchase price will not exceed 95 yuan/share, and the quantity is 21,500 to 421,100 shares, accounting for 0.04% to 0.07% of the total share capital. Funds are derived from own or self-raised funds, used for employee stock ownership plans or equity incentives, and cancelled if not used up within 3 years. It will be implemented within 12 months from review and approval by the board of directors. As of the disclosure date of the announcement, the relevant shareholders have no plans to reduce their A-share holdings for the next 3 or 6 months. Repurchases involve risks such as price and important matters.

Rongchang Biotech announced that the company plans to repurchase shares through centralized bidding transactions, with an amount not less than 20 million yuan and no more than 40 million yuan. The repurchase price will not exceed 95 yuan/share, and the quantity is 21,500 to 421,100 shares, accounting for 0.04% to 0.07% of the total share capital. Funds are derived from own or self-raised funds, used for employee stock ownership plans or equity incentives, and cancelled if not used up within 3 years. It will be implemented within 12 months from review and approval by the board of directors. As of the disclosure date of the announcement, the relevant shareholders have no plans to reduce their A-share holdings for the next 3 or 6 months. Repurchases involve risks such as price and important matters.